Company Information

Kitov Pharmaceuticals is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov’s veteran team of healthcare professionals maintains a proven track record in streamlined end-to-end drug development and approval. Kitov’s flagship combination drug, KIT-302, intended to treat osteoarthritis pain and hypertension simultaneously, achieved the primary efficacy endpoint for its Phase III clinical trial. Kitov’s newest drug, NT219, which is developed by its majority owned subsidiary, TyrNovo Ltd., is a small molecule that presents a new concept in cancer therapy, and in combination with various approved oncology drugs, demonstrated potent anti-tumor effects and increased survival in various cancer models.

Read More

Price Data
Recent News
Dec 14, 2017

Kitov Pharmaceuticals (NASDAQ: KTOV) (TASE: KTOV), an innovative biopharmaceutical company, announced today that the U.S. Food & Drug Administration (FDA) has granted permission to Kitov to use...

Nov 1, 2017

Kitov Pharmaceuticals (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, announced today that it has received the U.S. Food and Drug Administration's (FDA) response to the...

Oct 26, 2017

Results Validate Primary Efficacy Endpoint Achieved in Previous Successfully Completed Phase III Clinical Trial KIT-302 Reduces Creatinine Levels Indicating Improved Renal Function, Compared to...

More >

print email